Miguel Ángel Piris Pinilla-rekin lankidetzan egindako argitalpenak (8)

2019

  1. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2014

  1. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2013

  1. Erratum: MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma (Modern Pathology (2012) DOI; 10.1038/modpathol.2012.149)

    Modern Pathology

  2. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

    Modern Pathology, Vol. 26, Núm. 2, pp. 171-181

2012

  1. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases

    British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171

  2. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

    Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8

2004

  1. Influence of biologic markers on the outcome of Hodgkin's lymphoma: A study by the Spanish Hodgkin's Lymphoma Study Group

    Journal of Clinical Oncology, Vol. 22, Núm. 9, pp. 1664-1673